That came from John Erb at the CC , if you go and have a listen , that is what he says, pathway to approval will be quicker with new trial protocol and end points , patients will be monitored for 6 months for improvement and lead removed at 12 moths , plus new minimally invasive technology to install CP1 . Erb says he will not dilute shareholders at these low levels, That's a buy signal to me , cheers
SHC Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held